באדיבות מדיקונטקסט: Last Updated: 2001-07-25 15:27:45 EDT (Reuters Health)
WESTPORT, CT (Reuters Health) – A polymer stent system that slowly releases 7-hexanoyltaxol (QP2), a taxane analogue, appears to significantly reduce in-stent restenosis.
The QuaDS-QP2 stent (Quanam Medical Corp, Natick, Massachusetts) has QP2 loaded into a polymer biocompatible sleeve at 800 µg per 2.4 mm of the sleeve, according to a report in Circulation: Journal of the American Heart Association for July 24.
Dr. Peter J. Fitzgerald, from Stanford University, California, and colleagues studied QuaDS-QP2 stents implanted into 15 lesions in 14 patients–the first human trial of the system. During an average followup of 8.3 months, the investigators used serial intravascular ultrasound to evaluate neointimal tissue growth within the stent and at adjacent reference segments.
At followup, the researchers found that the mean neointimal area within the stented segments was 1.2 mm² and mean cross-sectional narrowing was 13.6%.
Cross-sectional narrowing with conventional stents ranges from 20% to 48%, Dr. Fitzgerald's group points out. The "lesser amount" of neointima seen in this study is similar to that found with radioactive and sirolimus-coated stents.
For the vessel segments immediately adjacent to the stent, the plaque area increased significantly by 1.3 to 1.4 mm². However, the researchers note that there were no significant changes in vessel, plaque or lumen area at the proximal or distal reference sites.
Dr. Fitzgerald and colleagues conclude that the new drug-delivery stent "shows favorable outcomes in the stented segment, with no evidence of significant marginal exacerbations."